Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

, Frontiers Production Office

doi:10.3389/fmed.2023.1289307

ERRATUM article

Front. Med. , 19 September 2023

Sec. Infectious Diseases: Pathogenesis and Therapy

Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1289307

Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

This article is an erratum on:

Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
1. Read original article

$\r\nFrontiers Production Office$ Frontiers Production Office^*

Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

by Wada, T., Hibino, M., Aono, H., Kyoda, S., Iwadate, Y., Shishido, E., Ikeda, K., Kinoshita, N., Matsuda, Y., Otani, S., Kameda, R., Matoba, K., Nonaka, M., Maeda, M., Kumagai, Y., Ako, J., Shichiri, M., Naoki, K., Katagiri, M., Takaso, M., Iwamura, M., Katayama, K., Miyatsuka, T., Orihashi, Y., and Yamaoka, K. (2023). Front. Med. 10:1139046. doi: 10.3389/fmed.2023.1139046

Due to a production error, an incorrect Conflict of Interest statement was provided. The correct Conflict of Interest statement appears below. The publisher apologizes for this mistake.

“The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

A reviewer of this manuscript, Devan Mehrotra, is a biostatistician at Merck & Co., Inc., known as MSD outside the United States and Canada. The pharmaceutical ivermectin studied in this manuscript is manufactured and marketed by Merck & Co., Inc. in the United States under the brand name STROMECTOL^®. After investigation, the journal has no reason to believe that the scientific conclusions of the article are affected in any way.”

The original article has been updated.

Keywords: double-blind, ivermectin, SARS-CoV-2 proliferation, RT-PCR test, Japan

Citation: Frontiers Production Office (2023) Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial. Front. Med. 10:1289307. doi: 10.3389/fmed.2023.1289307

Received: 05 September 2023; Accepted: 05 September 2023;
Published: 19 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good